Health
Ozempic’s Brain Impact Linked to Heart Benefits in Study
- Anti-inflammatory pathways in the brain may have wide effects
- Findings suggest GLP-1 drugs may help treat various diseases
This article is for subscribers only.
Brain signals in patients taking weight-loss drugs such as Novo Nordisk A/S’s Ozempic may contribute to lowering heart disease and deaths, researchers said.
Ozempic, Novo’s Wegovy and Eli Lilly & Co.’s Zepbound work in part by mimicking GLP-1, a hormone that moderates appetite and fights obesity, a known risk factor for heart disease. The drugs also activate anti-inflammatory pathways in the brain with far-reaching effects that may independently keep the heart healthy, according to a study.